Knopp Biosciences LLC reported today that Areteia Therapeutics Inc. announced the completion of a $75 million expansion of its Series A funding. The additional funds will be used to expand three ongoing Phase III clinical trials for dexpramipexole in the treatment of eosinophilic asthma. The financing was led by Bain Capital Life Sciences.
